ARTICLE | Clinical News
Staphylococcus lysin regulatory update
August 24, 2015 7:00 AM UTC
FDA granted Fast Track designation to ContraFect’s CF-301 to treat Staphylococcus aureus bloodstream infections, including methicillin-resistant S. aureus (MRSA). The company expects to complete a Pha...